The tetravalent bispecific antibody AFM13, with two binding sites for each CD30 and CD16A (FcγRIIIα), can recruit and activate CD16A+ NK cells to CD30-expressing tumor cells and can subsequently mediate tumor cell killing [140]. The gene discussed is FCGR3A; the disease is neoplasm.